ArticleJournal of clinical hypertension (Greenwich, Conn.)2019
Clinical outcomes and economic impact of the 2017 ACC/AHA guidelines on hypertension in China.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Blood pressure categories defined by the 2017 ACC/AHA guideline and all-cause mortality: a national cohort study in China and meta-analysis.Journal of human hypertension · 2022Pooled it
- Associations between social determinants and poor hypertension treatment adherence among middle-aged and older people in rural China: a hospital-based case‒control study.BMC public health · 2026Article
- Revisiting hypertension prevalence and risk factors: prevalence of hypertension and risk of diabetes in China.BMC cardiovascular disorders · 2025Article
- [Comparison of initiation of antihypertensive therapy strategies for primary prevention of cardiovascular diseases in Chinese population: A decision-analytic Markov modelling study].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024Article
- Cost-effectiveness of treatment in adults with blood pressure of 130-139/80-89 mmHg and high cardiovascular risk in China: a modelling study.The Lancet regional health. Western Pacific · 2024Article
- Cost-effectiveness of drug treatment for young and middle-aged stage 1 hypertensive patients with high risk.Journal of global health · 2023Article
- Report on cardiovascular health and diseases in China 2021: an updated summary.Journal of geriatric cardiology : JGC · 2023 · on this mapArticle
- Relationship between novel anthropometric indices and the incidence of hypertension in Chinese individuals: a prospective cohort study based on the CHNS from 1993 to 2015.BMC public health · 2023Article
- The relationship between serum C-reactive protein and senile hypertension.BMC cardiovascular disorders · 2022Article
- Blood pressure control and risk of post-stroke dementia among the elderly: A population-based screening study.Frontiers in neurology · 2022Article
- A comparative analysis and review of how national guidelines for chronic disease monitoring are made in low- and middle-income compared to high-income countries.Journal of global health · 2021Article
- Cost-Effectiveness of Drug Treatment for Chinese Patients With Stage I Hypertension According to the 2017 Hypertension Clinical Practice Guidelines.Hypertension (Dallas, Tex. : 1979) · 2020Article
- Insight into blood pressure targets for universal coverage of hypertension services in Iran: the 2017 ACC/AHA versus JNC 8 hypertension guidelines.BMC public health · 2020Article
- Highlights of the 2018 Chinese hypertension guidelines.Clinical hypertension · 2020Review
- Clinical outcomes and economic impact of the 2017 ACC/AHA guidelines on hypertension in China.Journal of clinical hypertension (Greenwich, Conn.) · 2019Article
- Contribution of Mitochondrial DNA Variation to Chronic Disease in East Asian Populations.Frontiers in molecular biosciences · 2019Review
- Regional impact of updated guidelines on prevalence and distribution of blood pressure categories for hypertension in India: Results from the National Family Health Survey 4.Indian heart journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 2017 guidelines on the diagnosis and treatment of high blood pressure in adults were published by the American College of Cardiology and the American Heart Association. The impact on clinical outcomes and costs needs to be estimated prior to adopting these guidelines in China. Data from a nationally representative sample in China were analyzed. The prevalence and treatment were calculated based on the criteria of the 2017 guidelines and 2018 Chinese guidelines among participants aged ≥35 years old. Direct medical costs, as well as the averted disability adjusted of life years and cost saving from cardiovascular disease events prevented by controlling hypertension, were also estimated. The prevalence and treatment rate of hypertension were 32.0% and 43.4% according to the 2018 Chinese guidelines. Based on the 2017 guidelines, another 24.5% of the adult population (estimated 168.1 million) would be classified as having hypertension; of whom, about 32.1 million would need to be pharmaceutically treated to reach the current treatment rate of 43.4%. As a result, an estimated additional 42.7 billion US dollars of the direct medical cost would be required for lifetime therapy. By preventing cardiovascular events, the new guidelines would reduce lifetime costs by 3.77 billion US dollars, while preventing 1.41 million disability adjusted of life years lost. Application of the 2017 guidelines in China will substantially increase the prevalence of hypertension and produce a large increase in therapy costs, although it would prevent cardiovascular disease events and save disability adjusted of life years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.